Fast Five Quiz: Secondary Prevention of Cardiovascular Disease

Yasmine S. Ali, MD


December 14, 2020

Statin therapy plays an important role for secondary prevention of CVD. In individuals ≤ 75 years of age who have clinical ASCVD, initiation of high-intensity statin therapy is recommended unless contraindicated. In cases where high-intensity statin therapy would be beneficial but is contraindicated, or in individuals who are predisposed to statin-associated adverse effects, moderate-intensity statin therapy, if tolerated, can be considered as a second-line option.

Among individuals ≥ 75 years with clinical ASCVD, the potential risk-reduction benefits, adverse effects, drug-drug interactions, and patient preferences of statin therapy should be assessed. When tolerated, statin therapy should be continued.

Cardiovascular disease specialists have discussed strategies and goals for CVD risk reduction in elderly individuals.

Learn more about secondary prevention of CVD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.